1. Home
  2. GXO vs ABVX Comparison

GXO vs ABVX Comparison

Compare GXO & ABVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GXO
  • ABVX
  • Stock Information
  • Founded
  • GXO 2021
  • ABVX 2013
  • Country
  • GXO United States
  • ABVX France
  • Employees
  • GXO N/A
  • ABVX N/A
  • Industry
  • GXO Transportation Services
  • ABVX
  • Sector
  • GXO Consumer Discretionary
  • ABVX
  • Exchange
  • GXO Nasdaq
  • ABVX Nasdaq
  • Market Cap
  • GXO 6.1B
  • ABVX 6.7B
  • IPO Year
  • GXO N/A
  • ABVX N/A
  • Fundamental
  • Price
  • GXO $53.93
  • ABVX $90.65
  • Analyst Decision
  • GXO Strong Buy
  • ABVX Strong Buy
  • Analyst Count
  • GXO 13
  • ABVX 9
  • Target Price
  • GXO $62.62
  • ABVX $94.11
  • AVG Volume (30 Days)
  • GXO 903.0K
  • ABVX 957.6K
  • Earning Date
  • GXO 11-04-2025
  • ABVX 08-11-2025
  • Dividend Yield
  • GXO N/A
  • ABVX N/A
  • EPS Growth
  • GXO N/A
  • ABVX N/A
  • EPS
  • GXO 0.53
  • ABVX N/A
  • Revenue
  • GXO $12,683,000,000.00
  • ABVX $7,073,400.00
  • Revenue This Year
  • GXO $13.70
  • ABVX $4.44
  • Revenue Next Year
  • GXO $6.38
  • ABVX N/A
  • P/E Ratio
  • GXO $101.42
  • ABVX N/A
  • Revenue Growth
  • GXO 22.39
  • ABVX N/A
  • 52 Week Low
  • GXO $30.46
  • ABVX $4.77
  • 52 Week High
  • GXO $63.33
  • ABVX $93.77
  • Technical
  • Relative Strength Index (RSI)
  • GXO 56.22
  • ABVX 74.86
  • Support Level
  • GXO $53.32
  • ABVX $85.00
  • Resistance Level
  • GXO $55.86
  • ABVX $90.70
  • Average True Range (ATR)
  • GXO 1.51
  • ABVX 2.98
  • MACD
  • GXO 0.20
  • ABVX -0.26
  • Stochastic Oscillator
  • GXO 72.29
  • ABVX 75.33

About GXO GXO Logistics Inc.

GXO Logistics Inc is a contract logistics company. Its revenue is diversified across numerous verticals and customers, including many multinational corporations. It provides warehousing and distribution, order fulfillment, e-commerce, reverse logistics, and other supply chain services differentiated by its ability to deliver technology-enabled, customized solutions at scale. Geographically, it generates revenue from the United Kingdom, the United States, the Netherlands, France, Spain, Italy, and other countries, and derives the majority of its revenue from the United Kingdom.

About ABVX Abivax SA American

Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD.

Share on Social Networks: